Truist lowered the firm’s price target on Viking Therapeutics (VKTX) to $95 from $120 and keeps a Buy rating on the shares. The company’s Q4 ...
Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback